Emerging Strategies in Bone Health Management for the Adjuvant Patient

Seminars in Oncology

Volumn 34, Issue SUPPL. 4, 2007, Pages

  Coleman, Robert E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CELL ADHESION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG INHIBITION; HISTOPATHOLOGY; HUMAN; LUNG TUMOR; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMIDAZOLES;

EID: 36549039108     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.10.003     Document Type: Article

References (26)

1. Mundy G.R. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2 (2002) 584-593
2. Peyruchaud O., Winding B., Pecheur I., et al. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: Application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 16 (2001) 2027-2034
3. Kavanagh K.L., Guo K., Dunford J.E., et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 103 (2006) 7829-7834
4. Rogers M.J., Gordon S., Benford H.L., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (2000) 2961-2978
5. Van Valckenborgh E., De Raeve H., Devy L., et al. Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br J Cancer 86 (2002) 796-802
6. Croucher P.I., De Hendrik R., Perry M.J., et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18 (2003) 482-492
7. Santini D., Vincenzi B., Battistoni F., et al. In vivo perspective study about the effects of weekly low dose administration of zoledronic acid (ZA) on angiogenesis. J Clin Oncol 25 suppl (2007) 152s (abstr 3558)
8. Denoyelle C., Hong L., Vannier J.-P., et al. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 88 (2003) 1631-1640
9. Coxon J.P., Oades G.M., Kirby R.S., et al. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 94 (2004) 164-170
10. Corey E., Brown L.G., Quinn J.E., et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9 (2003) 295-306
11. Giraudo E., Inoue M., and Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114 (2004) 623-633
12. Neville-Webbe H.L., Rostami-Hodjegan A., Evans C.A., et al. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113 (2005) 364-371
13. Ottewell P.D., Jones M., Lefley D.V., et al. Combined effects of cytotoxic drugs and anti-resorptive agents in vivo [poster] (2006) Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, (abstr 6102)
14. Sato K., Kimura S., Segawa H., et al. Cytotoxic effects of gamma-delta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 116 (2005) 94-99
15. Fiore F., Castella B., Nuschak B., et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity upon short-term incubation with zoledronic acid. Blood 110 (2007) 921-927
16. Hiraga T., Williams P.J., Ueda A., et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10 (2004) 4559-4567
17. Daubine F., Le Gall C., Gasser J., et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99 (2007) 322-330
18. Diel I.J., Solomayer E.F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339 (1998) 357-363
19. Saarto T., Vehmanen L., Virkkunen P., et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43 (2004) 650-656
20. Powles T., Paterson A., McCloskey E., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 8 (2006) R13-R20
21. Brufsky A., Harker W.G., Beck J.T., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25 (2007) 829-836
22. Mystakidou K., Katsouda E., Parpa E., et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 22 (2005) 195-201
23. Rack B.K., Janni W., Schindlbeck C., et al. Effect of zoledronate on persisting isolated tumor cells (ITC) in the bone marrow (BM) of patients without recurrence of early breast cancer. Proc Am Soc Clin Oncol 23 suppl (2004) 843 (abstr 9515)
24. Coleman R.E., Thorpe H., Cameron D., et al. Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy-First safety data from the AZURE trial (BIG01/04) [poster] (2006) Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, (abstr 2080)
25. Smid M., Wang Y., Klijn J.G.M., et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 24 (2006) 2261-2267
26. Papotti M., Kalebic T., Volante M., et al. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: A retrospective case-control study. J Clin Oncol 24 (2006) 4818-4824